CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 69 target
Drug / intervention
ABX + DDP +2 moredrug
Likely dose
ABX + DDP 260 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01735409
NCT01735409Phase 2Unknown
CompareCT.gov

A Single Center Phase IIa Study of Nanoparticle Albumin-bound Paclitaxel in Combination With Cisplatin in Advanced Nasopharyngeal Carcinoma

Sun Yat-sen University·interventional·Posted Nov 28, 2012·Updated Jan 28, 2014

In Brief

A Phase 2 clinical trial evaluating ABX + DDP for Nasopharyngeal Neoplasms. Targeting 69 participants across 1 site.

Detailed Summary

This is a single center, non-randomized phase IIa study to determine the tolerance and safety of Abraxane (ABX) in combination with cisplatin (DDP) in patients with advanced nasopharyngeal carcinoma (NPC). Patients in whom the standard therapy had failed or had been infeasible will be eligible.The safety and efficacy will be evaluated according to NCI-CTCAE V4.0 and RECIST 1.1 respectively.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Neoplasms
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20132014201520162017201820192020202120222023202420252026
First PostedNov 28, 2012
Enrollment StartNov 1, 2012
Primary CompletionMar 1, 2014
Study CompletionJun 1, 2014
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 13.6 years ago

Interventions

ABX + DDPdrug

ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1

ABX + DDPdrug

ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1

ABX + DDPdrug

ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1